This week we look at gammaCore™ for cluster headache, warnings of stroke risk with a multiple sclerosis drug and a gene therapy for spinal muscular atrophy.
Browsing: Development and pediatrics
The EMA has approved Gilenya® (fingolimod) for the treatment of children and adolescents with relapsing–remitting forms of multiple sclerosis.
A team of researchers have devised a novel method of diagnosing autism in children. Following analysis of short home videos of children, mathematical modelling was utilized to provide a numerical score indicating the severity of the developmental disorder.
Research presented at SfN has provided insight into the neural risks and benefits of marijuana use, including development and Alzheimer’s disease.
Three studies have been highlighted at SfN Neuroscience on the links between adolescent brain development, mental health and substance abuse.
Gene therapy for disorders such as amyotrophic lateral sclerosis, Parkinson’s disease and Batten disease has seen success in animal models.
For the first time in the UK, a team of surgeons have operated on abnormally developed spinal cords of two fetuses with spina bifida.
Scientists at The Wellcome Sanger Institute have determined that the risk of suffering from a range of monogenic neurodevelopmental genetic disorders can be affected by common genetic variations.
Whilst at FENS 2018, we spoke with Arnold Kriegstein on his work with cerebral organoids in brain development, and how we might define a cell’s maturity.
A novel study has revealed that elevated pesticide levels in pregnant women are associated with an increased risk of autism among their children.